{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Srinivasa S"],"funding":["National Center for Advancing Translational Sciences","National Center for Research Resources","National Institutes of Health","Harvard Catalyst"],"pagination":["bvab175"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8664688"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["Subclinical myocardial dysfunction is prevalent among well-treated persons with HIV (PWH). We have previously demonstrated unique renin-angiotensin-aldosterone system physiology among PWH with metabolic dysregulation. Mineralocorticoid receptor blockade may be a targeted treatment strategy for subclinical heart disease in PWH. Forty-six PWH were randomized to receive either eplerenone 50 mg daily or placebo in a 6-month randomized, double-blinded, placebo-controlled trial. We assessed changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of cardiac stretch, under controlled posture and dietary conditions. The eplerenone- and placebo-treated groups demonstrated a long duration of HIV with good immunological control. NT-proBNP levels were similar between the groups at"],"journal":["Journal of the Endocrine Society"],"pubmed_title":["Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV."],"pmcid":["PMC8664688"],"funding_grant_id":["R01 HL15129","R01 DK49302","UL1 RR025758","UL1 TR001102","P30 DK040561","K24 HL103845","K23 HL136262","UL1 TR000170"],"pubmed_authors":["Fitch KV","Srinivasa S","Adler GK","Thomas TS","deFilippi C","Iyengar S","Burdo TH","Walpert AR","Grinspoon SK","Shen G"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV.","description":"Subclinical myocardial dysfunction is prevalent among well-treated persons with HIV (PWH). We have previously demonstrated unique renin-angiotensin-aldosterone system physiology among PWH with metabolic dysregulation. Mineralocorticoid receptor blockade may be a targeted treatment strategy for subclinical heart disease in PWH. Forty-six PWH were randomized to receive either eplerenone 50 mg daily or placebo in a 6-month randomized, double-blinded, placebo-controlled trial. We assessed changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of cardiac stretch, under controlled posture and dietary conditions. The eplerenone- and placebo-treated groups demonstrated a long duration of HIV with good immunological control. NT-proBNP levels were similar between the groups at","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T03:57:51.304Z","creation":"2022-02-11T14:05:27.349Z"},"accession":"S-EPMC8664688","cross_references":{"pubmed":["34909518"],"doi":["10.1210/jendso/bvab175"]}}